SwePub
Sök i LIBRIS databas

  Utökad sökning

id:"swepub:oai:DiVA.org:uu-396717"
 

Sökning: id:"swepub:oai:DiVA.org:uu-396717" > Lowered anti-beta1 ...

  • Ernst, DianaMed Sch Hannover, Dept Immunol & Rheumatol, Hannover, Germany (författare)

Lowered anti-beta1 adrenergic receptor antibody concentrations may have prognostic significance in acute coronary syndrome

  • Artikel/kapitelEngelska2019

Förlag, utgivningsår, omfång ...

  • 2019-10-10
  • NATURE PUBLISHING GROUP,2019
  • electronicrdacarrier

Nummerbeteckningar

  • LIBRIS-ID:oai:DiVA.org:uu-396717
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-396717URI
  • https://doi.org/10.1038/s41598-019-51125-9DOI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:ref swepub-contenttype
  • Ämneskategori:art swepub-publicationtype

Anmärkningar

  • Although several risk factors exist for acute coronary syndrome (ACS) no biomarkers for survival or risk of re-infarction have been validated. Previously, reduced serum concentrations of anti-beta(1)AR Ab have been implicated in poorer ACS outcomes. This study further evaluates the prognostic implications of anti-beta(1)AR-Ab levels at the time of ACS onset. Serum anti-beta(1)AR Ab concentrations were measured in randomly selected patients from within the PLATO cohort. Stratification was performed according to ACS event: ST-elevation myocardial infarct (STEMI) vs. non-ST elevation myocardial infarct (NSTEMI). Antibody concentrations at ACS presentation were compared to 12-month all-cause and cardiovascular mortality, as well as 12-month re-infarction. Sub-analysis, stratifying for age and the correlation between antibody concentration and conventional cardiac risk-factors was subsequently performed. Serum anti-beta(1)AR Ab concentrations were measured in 400/799 (50%) STEMI patients and 399 NSTEMI patients. Increasing anti-beta(1)AR Ab concentrations were associated with STEMI (p = 0.001). Across all ACS patients, no associations between anti-beta(1)AR Ab concentration and either all-cause cardiovascular death or myocardial re-infarction (p = 0.14) were evident. However among STEMI patients <60 years with anti-beta(1)AR Ab concentration median (14/198 (7.1%) vs. 2/190 (1.1%)); p = 0.01). Similarly, the same sub-group demonstrated greater risk of cardiovascular death in year 1, including re-infarction and stroke (22/198 (11.1%) vs. 10/190 (5.3%); p = 0.017). ACS Patients <= 60 years, exhibiting lower concentrations of beta(1)AR Ab carry a greater risk for early re-infarction and cardiovascular death. Large, prospective studies quantitatively assessing the prognostic relevance of Anti-beta(1)AR Ab levels should be considered.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Westerbergh, JohanUppsala universitet,Uppsala kliniska forskningscentrum (UCR)(Swepub:uu)johwe257 (författare)
  • Sogkas, GeorgiosMed Sch Hannover, Dept Immunol & Rheumatol, Hannover, Germany (författare)
  • Jablonka, AlexandraMed Sch Hannover, Dept Immunol & Rheumatol, Hannover, Germany (författare)
  • Ahrenstorf, GerritMed Sch Hannover, Dept Immunol & Rheumatol, Hannover, Germany (författare)
  • Schmidt, Reinhold ErnstMed Sch Hannover, Dept Immunol & Rheumatol, Hannover, Germany (författare)
  • Heidecke, HaraldCellTrend GmbH, Luckenwalde, Germany (författare)
  • Wallentin, Lars,1943-Uppsala universitet,Kardiologi,Uppsala kliniska forskningscentrum (UCR)(Swepub:uu)larswall (författare)
  • Riemekasten, GabrielaUniv Schleswig Holstein, Dept Rheumatol, Lubeck, Germany (författare)
  • Witte, TorstenMed Sch Hannover, Dept Immunol & Rheumatol, Hannover, Germany (författare)
  • Med Sch Hannover, Dept Immunol & Rheumatol, Hannover, GermanyUppsala kliniska forskningscentrum (UCR) (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:Scientific Reports: NATURE PUBLISHING GROUP92045-2322

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy